่In an analysis limited to participants who developed diabetes during the JUPITER trial (n=270 on rosuvastatin, 216 on placebo), 18 primary cardiovascular endpoints occurred. Of these, eight were on rosuvastatin (incidence rate 1·10 per 100 person-years) and ten were on placebo (1·73 per 100 person-years). Thus, among the 486 JUPITER trial participants who developed diabetes during follow- up, the cardiovascular risk reduction associated with rosuvastatin (HR 0·63, 95% CI 0·25–1·60) was consistent with that for the trial as a whole (0·56, 0·46–0·69).